Literature DB >> 30740509

Is epicardial fat tissue associated with atrial fibrillation recurrence after ablation? A systematic review and meta-analysis.

Alireza Sepehri Shamloo1, Nikolaos Dagres1, Boris Dinov1, Philipp Sommer1, Daniella Husser-Bollmann1, Andreas Bollmann1, Gerhard Hindricks1, Arash Arya1.   

Abstract

INTRODUCTION: Although an undoubted association between epicardial fat tissue (EFT) and atrial fibrillation (AF) has been recently approved, the association between EFT and post-ablation AF recurrence is not evident yet. This study aimed to assess the association between EFT and AF recurrence after ablation.
METHODS: The present study was a systematic review and meta-analysis using related literature available in electronic databases until July 2018 via "atrial fibrillation" and "epicardial fat" as the main keywords. Considering the different methods of EFT measurement, three different pooled meta-analyses were conducted in this study including: 1) comparison of total EFT volume, 2) left atrium (LA)-EFT volume, and 3) EFT thickness between two groups with and without AF recurrence estimating standardized mean difference (SMD) through a random and non-random effect meta-analysis. Statistical analysis was also performed using Comprehensive Meta-analysis (CMA) Software.
RESULTS: Following a search into a total number of 518 articles, the findings of 12 studies published in 10 articles were enrolled in this meta-analysis. Accordingly, the results of meta-analysis showed that LA-EFT and total EFT volumes were higher in recurrent subjects (LA-EFT: SMD = 0.862 ml; I2 = 0.00, 95% confidence interval (CI) = 0.567-1.156; total EFT: SMD = 1.017 ml, I2 = 0.00, 95% CI = 0.748-1.286). Besides, a significant higher EFT thickness in patients with AF recurrence compared to those with no AF recurrence was observed (SMD = 0.808 mm, I2 = 91.07, 95% CI = 0.215-1401).
CONCLUSION: The total EFT and LA-EFT volumes, as well as EFT thickness, seemed to be associated with AF recurrence in patients undergoing AF ablation.

Entities:  

Keywords:  Adipose tissue; Atrial fibrillation; Epicardial fat; Prognosis; Recurrence; Risk assessment

Year:  2019        PMID: 30740509      PMCID: PMC6356021          DOI: 10.1016/j.ijcha.2019.01.003

Source DB:  PubMed          Journal:  Int J Cardiol Heart Vasc        ISSN: 2352-9067


Introduction

Atrial fibrillation (AF) is known as the most common sustained supraventricular arrhythmia with an increasing global incidence and prevalence [1]. Rhythm control strategies, mainly with catheter ablation (CA) or cryoballon ablation (CBA), have also become optimal and well-established treatment options in the domain of symptomatic AF [2]. However, ablation therapy as an interventional procedure has still brought about various issues regarding procedural complications, high expenditure, as well as arrhythmia recurrence [3]. Moreover, the success rate of AF ablation has been only reported by 70% in patients with paroxysmal AF (PAF) and 50% in persistent AF (PeAF), which means that the recurrence rate of a single ablation procedure ranges from 30 to 50% [4]. In fact, the high acute success rates for CA procedure are deemed to be achievable and its durable efficacy for AF has remained the main challenge [4,5]. Thus, appropriate patient selection considering the prediction factors of AF recurrence after an initially successful ablation has also become a significant issue for obtaining better outcomes [6]. In this regard, different clinical and para-clinical factors including older age, female gender, classical cardiovascular risk factors, non-paroxysmal AF, left ventricular (LV) dysfunction, myocardial fibrosis, and atrial enlargement have been further identified as possible predictors of post-ablation AF recurrence [7,8]. Epicardial fat tissue (EFT), as a specialized visceral adipose tissue, has been also considered as an endocrine organ producing various pro-inflammatory and pro-atherogenic factors such as leptin, IL-6, adipocytokines, and TNF-alpha that promote the initiation and development of coronary artery atherosclerosis [9]. The EFT has been also suggested to play a significant role in promoting arrhythmogenesis due to its pro-inflammatory properties and anatomical proximity to the myocardium [10,11].Correspondingly, some believe that EFT has an additional role in the modulation of different triggers, including metabolic and biochemical triggers, leading to AF [12]. The relationship between increase in EFT amount and AF occurrence and severity has been similarly shown in several recent studies [13]. Moreover, the association between EFT and AF recurrence after ablation is not evident yet although newly conducted meta-analysis comparing EFT volume in healthy and AF subjects has revealed an undoubted association between EFT and AF [14]. The abundance of EFT and post-ablation AF recurrence was firstly described by Tsao et al.; while more than ten different studies have investigated this association up to now [15]. However, these studies have been conducted in different populations, various disease stages (paroxysmal or persistent AF), a variety of EFT measurement methods (computed tomography (CT) or echocardiography), numerous methods of rhythm control strategy (CA or CBA), and diverse intervals of follow-up for AF recurrence [[16], [17], [18], [19], [20], [21], [22], [23], [24]]. The present study was the first attempt to verify the association between AF recurrence and EFT, conducting a meta-analysis of investigations comparing patients with and without AF recurrence after ablation.

Methods

Protocol

This systematic review and meta-analysis conducted by the principles set in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA Statement [25].

Eligibility criteria and study selection

Studies were included if they were: 1) reported EFT thickness or volume with any statistical indexes, 2) reported EFT parameters in two groups of patients with and without AF recurrence after ablation, and 3) measured EFT by CT, magnetic resonance imaging (MRI), or echocardiography. Studies published as conference abstracts were considered eligible for inclusion; however, case reports and review articles were excluded. These articles were independently reviewed by two assessors to ensure full compliance with the study inclusion and exclusion criteria and were discussed and revised in the cases of disagreements.

Information sources and search

Databases including MEDLINE/PubMed, EBSCO, Thomson Reuters' Web of Science, the Cochrane Library, and Google Scholar, were searched since inception until July 2018 using the following keywords: “Atrial fibrillation; Arrhythmias, Cardiac; Adipose Tissue, Epicardial adipose, Epicardial fat, Epicardial adipose tissue.” Titles and abstracts were screened for the exclusion of unrelated articles. Also, the references of all finally included articles were reviewed in case of finding any related article. No language restrictions were assumed for the included articles.

Data collection process

Using a data extraction table, the required information from each article including first authors name, publication year, study design, sample size, method of AF ablation (CA or CBA), imaging method of EFT measurement (CT, MRI, or Echocardiography), type of reported EFT (thickness or volume), the location of measured EFT, and follow-up duration for AF recurrence were extracted. The table was completed by the first author and checked by another author for verifying.

Quality assessment

The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement was used to assess the quality of the included studies with full-text [26]. The STROBE contained 22 items for quality assessment of the information reported in different sections of a study including introduction, study design and setting, statistical evaluation, results, discussion, and findings. A summary of the results of STROBE judgment for all finally included studies was prepared based on a rating scale ranging from 0 to 22. Quality assessment was performed by two different assessors and a third assessor in case of discrepancies. In the case of conference abstracts, studies without full-text, another type of STROBE checklist, contained 12 items to be included when reporting observational studies in a conference abstract, was used.

Summary measures and synthesis of results

The PRISMA declaration was followed for statistical analysis. Q statistic of Chi-square value test and I2 index (inconsistency index) were used to evaluate the heterogeneity of individual studies contributing to the pooled estimate. I2 > 50% suggested heterogeneity [27]. P < 0.05 was considered statistically significant, suggesting the presence of heterogeneity. In the case of heterogeneity, a random effects model was used. Probable sources of heterogeneity through the studies were explored using meta-regression and subgroup analysis. The probability of publication bias was evaluated through the Egger's regression test and Funnel plots [28]. The funnel plots exhibit a graphical representation of possible publication bias so that any asymmetry in the plot can represent publication bias, and Egger's regression is also the statistical counterpart of this asymmetry. Considering the different methods of EFT measurement, three different pooled meta-analyses were done in this systematic review including 1) comparison of total EFT volume, 2) LA-EFT volume, and 3) EFT fat thickness between two groups of with and without recurrence AF. All statistical tests were two-tailed and the type I error rate was set at 5%. Statistical analysis was performed using Comprehensive Meta-analysis (CMA) version 2.

Results

Study selection

The literature search resulted in 518 records. After exclusion of 194 duplicated records, of the 324 remaining records, 294 were not related to the topic. After assessing the full texts of 30 remaining studies, 20 of the articles excluded. Finally, the findings of the 12 studies published in 10 articles were enrolled in this study (Fig. 1). Finally, three different pooled meta-analyses were done, assessing the association of total EFT volume (n = 4), LA-EFT volume (n = 4), and EFT fat thickness (n = 4) between two groups of with and without recurrence AF.
Fig. 1

PRISMA flow chart of included studies.

EFT: epicardial fat tissue, LA: left atrium.

PRISMA flow chart of included studies. EFT: epicardial fat tissue, LA: left atrium.

Excluded studies

Twenty studies were excluded after reviewing the original text for the following reasons: 1) lack of reporting EFT, and considering pericardial adipose tissue as the main outcome (n = 2); 2) using electrical cardioversion, not ablation for AF (n = 1); and 3) no comparison between two groups of with and without AF recurrence was available (n = 17).

Study characteristics

The analysed studies had included 1208 individuals including patients with AF recurrence (n = 816) and without AF recurrence (n = 392) after ablation. Among the AF patient, 889 patients had PAF, and 333 had PeAF. Most of the articles (7/10) were in the full-text format, while three articles were in the conference abstract [17,19,20]. CT [[15], [16], [17],[19], [20], [21], [22], [23]] and echocardiography [18,24] were the used imaging modalities for EFT measurements. The least sample size was 38 [17], and the largest ones were related to Chao et al., [18] with 283 patients. The first article was published in 2011 [15], and the latest article in 2016 [24] (Table 1). Other characteristics of the included studies including study location, type of ablation, follow-up duration, age, body mass index (BMI), and gender distribution are shown in Table 2.
Table 1

Characteristics of the included studies.

ReferenceYearSample size (PAF/PeAF)AF recurrence
No AF recurrence
Type of EATImagingArticle typeQuality score
nMean ± SDanMean ± SDa
Tsao [15]201168 (43/25)2435.2 ± 12.54426.8 ± 11.1LA-EFT volumeCTOA18/22
Nagashima [16]201140 (24/16)15239 ± 90.225153.5 ± 42.7Total EFT volumeCTOA18/22
1569.6 ± 35.52540.7 ± 13.9LA-EFT volumeCT
Murakami [17]201238 (32/6)12200 ± 6226145 ± 37Total EFT volumeCTCA5/12
Chao [18]2013227 (all PAF)646.3 ± 0.61495.7 ± 0.6RV wall EFT thicknessEchoOA19/22
56 (all PeAF)317.3 ± 0.6256.7 ± 0.7RV wall EFT thicknessEcho
Kawakami [19]201395 (74/21)34147.3 ± 35.861109.5 ± 34.9Total EFT volumeCTCA4/12
Soucek [20]2014102 (74/28)27115.8 ± 38.27586.6 ± 38.2Total EFT volumeCTCA5/12
Nakahara [21]201460 (0/60)4733.2 ± 10.71325.1 ± 11LA-EFT volumeCTOA18/22
Masuda [22]201553 (22/31)2435.1 ± 13.12925.0 ± 9.5LA-EFT volumeCTOA22/22
Kocyigit [23]2015249 (203/46)604.4 ± 2.11894.3 ± 1.6RV wall EFT thicknessCTOA19/22
Canpolat [24]2016234 (190/44)457.79 ± 2.21895.79 ± 1.38RV wall EFT thicknessEchoOA19/22

PAF/PeAF: paroxysmal/persistent atrial fibrillation; LA: left atrium; EAT: epicardial adipose tissue, CT: computed tomography; OA: original article; CA: conference abstract; RV: right ventricle; Echo: echocardiography.

Notice: Unit of the volume and thickness variables are milliliter (ml) and millimeter (mm), respectively.

Table 2

Settings and baseline characteristics of the included studies.

ReferenceLocationType of ablationAge, years
Gender, male (%)
BMI, kg/m2
Follow/up duration
AF Rec (−)AF Rec (+)AF Rec (−)AF Rec (+)AF Rec (−)AF Rec (+)
Tsao [15]TaiwanRFCA53.3 ± 9.057.1 ± 7.134 (77%)18 (75%)25.3 ± 3.026.2 ± 3.93 months
Nagashima [16]JapanRFCA56.4 ± 11.060.7 ± 8.518 (72.0%)13 (86.7%)22.4 ± 2.424.1 ± 2.63–6 month
Murakami [17]JapanRFCAN/AN/AN/A3 months
Chao [18]TaiwanRFCATotal: 54.6 ± 10.4Total: 197 (69.6%)Total: 25.3 ± 3.616 ± 9 months
Kawakami [19]JapanRFCATotal: 60.5 ± 11.8Total: 73 (76.8)N/AOne year
Soucek [20]USARFCAN/ATotal: 85 (83.3)N/A3 months
Nakahara [21]JapanRFCATotal: 63.1 ± 10.4Total: 50 (83%)NA16.0 (12–16) months
Masuda [22]JapanRFCA61 ± 1362 ± 922 (76)14 (58)24.3 ± 3.224.0 ± 3.216 ± 4 months
Kocyigit [23]TurkeyCryo55.1 ± 10.756.9 ± 10.486 (45.5)34 (56.7)24.2 ± 1.624.4 ± 1.629 (8–48) months
Canpolat [24]TurkeyCryo53.1 ± 10.657.8 ± 10.894 (49.7%)26 (57.8%)25.3 ± 5.226.0 ± 3.320 (13–24) months

Rec: recurrence; BMI: body mass index; N/A: not available; RFCA: radio frequency catheter ablation; Cryo: cryoballon ablation.

Characteristics of the included studies. PAF/PeAF: paroxysmal/persistent atrial fibrillation; LA: left atrium; EAT: epicardial adipose tissue, CT: computed tomography; OA: original article; CA: conference abstract; RV: right ventricle; Echo: echocardiography. Notice: Unit of the volume and thickness variables are milliliter (ml) and millimeter (mm), respectively. Settings and baseline characteristics of the included studies. Rec: recurrence; BMI: body mass index; N/A: not available; RFCA: radio frequency catheter ablation; Cryo: cryoballon ablation.

Total epicardial fat volume

The comparison of total EFT volume between two groups of patients with and without AF recurrence using a random effect model showed an SDM of 1.02 ml (95% CI = 0.74–1.28), indicating that EFT volume was higher in AF recurrence patients. No significant heterogeneity was observed among the studies' results (P = 0.526, Q-value = 2.29, df (Q) = 3, I2 = 0.0%) (Fig. 2-A).
Fig. 2

(A) Fixed effect meta-analysis comparing total EFT volume of patients with AF recurrence and without AF recurrence; (B) fixed effect meta-analysis comparing left atrium (LA)-EFT volume of patients with AF recurrence and without AF recurrence; (C) random effect meta-analysis comparing epicardial fat tissue (EFT) thickness of patients with AF recurrence and without AF recurrence.

(A) Fixed effect meta-analysis comparing total EFT volume of patients with AF recurrence and without AF recurrence; (B) fixed effect meta-analysis comparing left atrium (LA)-EFT volume of patients with AF recurrence and without AF recurrence; (C) random effect meta-analysis comparing epicardial fat tissue (EFT) thickness of patients with AF recurrence and without AF recurrence.

Left atrium epicardial fat volume

About the association between the LA-EFT volume and the AF recurrence, there was a significant difference in the SDM between patients with and without AF recurrence (0.86 ml, 95% CI = 0.56–1.15), showing a higher LA-EFT volume in AF recurrence patients. The heterogeneity was not found among the studied studies (P = 0.731, Q-value = 1.29, df (Q) = 3, I2 = 0.0%,) using the fixed effect model (Fig. 2-B).

Epicardial fat thickness

The patients with AF recurrence had a significant higher echocardiographic EFT thickness than those without AF recurrence (SDM = 0.80, 95% CI = 0.21–1.40). Considering the founded heterogeneity among the studied studies (P = 0.000, Q-value = 33.60, df (Q) = 33.60, I2 = 91.07%), the random effect model was used (Fig. 2-C).

Quality assessment and publication bias

All studies in the current meta-analysis were not of the same quality; the lowest STROBE score was 18, and the highest was 22 for the articles with full-text (Table 1). Description of any efforts to address potential sources of bias was not clear in most of the articles with full-text (6/7). Moreover, the eligibility criteria and the sources and methods of selection of participants were not also clear in 90.0% of the articles. Regarding the Egger's regression test (P = 0.187), there was no published bias in the studies (Fig. 3).
Fig. 3

Illustration of funnel plot asymmetry due to heterogeneity including all studies.

Illustration of funnel plot asymmetry due to heterogeneity including all studies.

Discussion

Summary of main results

The main findings of the present study showed an association between increased EFT and AF recurrence. In this respect, three different meta-analyses were conducted to investigate the association between EFT volume, both total and LA specified EFT, as well as EFT thickness on right ventricle free-wall and post-ablation AF recurrence. The findings were all in a similar line, showing a positive association between increased EFT and AF recurrence. Surprisingly, the present meta-analysis demonstrated a significant difference in EFT thickness between two groups with and without AF recurrence; similar to what was reported by CT about EFT volumes. These findings put emphasis on the importance of further evaluations on EFT reports about echocardiography, as a safe and non-invasive imaging modality [29]. Furthermore, the present study, as the first attempt to clarify the association between EFT and AF recurrence revealed a new possible imaging marker for the prediction of AF recurrence, which required further carefully-designed studies for more accurate evaluations.

Why was this meta-analysis important?

While it is still unclear how EFT affects electrical and structural AF substrates, there are some mechanisms including electrical remodeling, inflammation, oxidative stress, genetic factors, neural mechanism, and aromatase estrogenic capacity that can be taken into account [[30], [31], [32]]. The findings of this study suggested that an increased amount of EFT was much more popular in cases of post-ablation AF recurrence, implying the importance of EFT reduction as a part of strategic planning for AF recurrence prevention. However, the effect of EFT reduction on the outcomes of AF ablation required different clinical trials, but the evidence from observational studies reviewed in this study supported the probable beneficial effects of EFT decline on post-ablation AF recurrence reduction. The study argument was also put on the grounds that: 1) EFT had a strategic location, which was mostly accumulated between the myocardium and the visceral pericardium, without any separating structure from the myocardium and the epicardial vessels [10,33,34]; 2) aside from the approved mechanisms of EFT effects on arrhythmia, EFT might have an effect on triggers from different sites, mainly pulmonary veins, that could interact with a remodelled atrial substrate to sustain AF [12]; 3) association between EFT and AF incidence had been proven in a recent meta-analysis [14], and 4) the present meta-analysis showed the evidence of EFT effects on AF recurrence. In fact, it was assumed that EFT reduction would have more beneficial effects on the outcomes of ablation rather than whole body weight loss through a targeted therapy strategy; however, the impact of whole body weight loss on the EFT reduction was certainly not negligible [35,36]. Likewise, it should be noted that weight loss and statins are so far the only recommended solutions for EFT reduction, and other therapeutic agents such as Eicosapentaenoic acid and Botulinum toxin are even now on their initial phases of clinical trials [[37], [38], [39]].

Comparison with other meta-analyses

Although the association between the amount of EFT and AF has been recently approved in another meta-analysis [14], the present study was the first meta-analysis on the association between EFT and post-ablation AF recurrence. Therefore, the findings of this meta-analysis were incomparable to another review study in this domain. However, the present meta-analysis, similar to other recent meta-analyses, helped to find another piece of the puzzle of EFT and AF association. In Gaeta et al., the piece of the association between EFT and AF incidence or prevalence was merely found; while in the present study, the piece of association between EFT and AF recurrence was completed.

Causes of heterogeneity

One of the most interesting points about this meta-analysis was the method of classification of studies in three categories of LA-EFT volume, total EFT volume, and EFT thickness. Using this approach, the evident source of heterogeneity among studies was reduced; wherein no heterogeneity was reported in two meta-analyses of comparing EFT volumes in two groups with and without AF recurrence. Although, the I2 index was found to be 0.0% for meta-analysis of EFT volumes, including LA and total-EFT; it was reported to be >90% for EFT thickness, indicating the presence of heterogeneity sources among the studies. Given the obtained heterogeneity, the random effect model was used in EFT thickness meta-analysis. Considering the number of studies, a subgroup analysis could not be performed to find the possible sources of heterogeneity among various probable factors such as female gender, ablation type, AF type (PAF or PeAF), and criteria used to define AF recurrence, as well as quality of studies based on STROBE Checklist. Moreover, BMI and age, as well as other classical coronary artery disease (CAD) risk factors were additional possible sources of heterogeneity whose role was impossible to be assessed as the sources of heterogeneity with meta-regression due to no reference to them in the majority of studies. However, in another meta-analysis, it had been reported that EFT was not only associated with AF independently from the presence of classical CAD risk factors, but also the EFT amount was regarded as a better risk marker associated with arrhythmia.

Overall completeness, applicability, and quality of evidence

The number of high-quality studies investigating the association between EFT and AF incidence and prevalence seemed not to be enough to reach a definite conclusion. Although a strong association was found in this study showing that people with AF recurrence had an increased volume and thickness of EFT, the included evidence in this meta-analysis was not sufficient considering its quantity and quality. So, it is believed that there is still a long way to go for an undoubted approval of the association between increased EFT and a higher risk of AF recurrence. Considering the low number of studies in this field, there were attempts to include as much study as possible in this meta-analysis, taking no notice of the quality of the reported evidence, which reduced the strength of the results of this study for generalization. In this regard, three studies without any full-texts were included, which had been only published as abstracts in conference abstract books, as well as three investigations with a quality score equal to 18 (of 22). A total number of 1222 patients, from 10 articles, were included in this systematic review, and the number of patients reached around 250–750 individuals in each meta-analysis, which seemed little for the generalization of the results. Besides, the prospective design for studies was evident in only two cases, and most of the investigations did not bring up their retrospective or prospective approaches in the process of data collection.

Study limitations

All the included studies in this meta-analysis had an observational design, which by itself had no high position among the Evidence-Based Medicine Pyramid (EBMP). Besides, all the included studies were single-center trials with small sample size. On the other hand, the findings of some studies were limited only to a three-month follow-up. Another limitation in the given studies might be the presence of reporting bias; therefore, AF recurrence as a complication of AF ablation might have been underestimated in some studies. Moreover, we could not adjust our results based on age, gender, and major CAD risk factors, since not all the studies have reported any adjustment for these possible confounders.

Conclusions

According to the findings of the present meta-analysis, the EFT measurement, both volume and thickness measurements, seemed to be acceptable strategies for risk stratification of AF recurrence. The present meta-analysis showed that total and LA-EFT volumes, as well as EFT thickness, were higher in patients with AF recurrence in comparison to those without AF recurrence after ablation. However, the amount of evidence in this regard is still inadequate, requiring further cohort studies.

Implications for further research

Future studies would be required to indicate which type and what protocol of imaging as well as which location of EFT measurement can be the best choices for risk stratification. Moreover, further studies with longer follow-up periods as well as larger sample sizes, are still needed to assess the EFT between two groups with and without AF recurrence. Furthermore, achieving a certain cut-off point from the echocardiographic thickness of EFT and total or LA-EFT are expected to be a challenging issue for future prediction of post-ablation AF recurrence, and this could be also a good idea for future studies.

Implications for practice

Based on this meta-analysis, it seemed that clinicians should evaluate the EFT, whether as EFT thickness by echocardiography or as EFT-volume via CT, as a possible imaging marker for a better assessment of AF ablation clinical outcomes. Thus; lowering the amount of EFT after ablation, using the available strategies such as weight loss or statin therapy, might be useful for moderating the risk of post-ablation AF recurrence.

Author contributions

Alireza Sepehri Shamloo, Nikolaos Dagres, Arash Arya: Concept/design, Data analysis/interpretation, Drafting article, Approval of article. Boris Dinov, Philipp Sommer, Daniella Husser-Bollmann, Andreas Bollmann, Gerhard Hindricks: Concept/design, Critical revision of article, Approval of article.

Conflict of interests

N.D. and G.H. report research grants from Abbott, Biotronik, Boston Scientific and Medtronic to the institution (Heart Center Leipzig) without personal financial benefits.
  34 in total

Review 1.  Measuring inconsistency in meta-analyses.

Authors:  Julian P T Higgins; Simon G Thompson; Jonathan J Deeks; Douglas G Altman
Journal:  BMJ       Date:  2003-09-06

2.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.

Authors:  David Moher; Alessandro Liberati; Jennifer Tetzlaff; Douglas G Altman
Journal:  Int J Surg       Date:  2010-02-18       Impact factor: 6.071

3.  The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies.

Authors:  Erik von Elm; Douglas G Altman; Matthias Egger; Stuart J Pocock; Peter C Gøtzsche; Jan P Vandenbroucke
Journal:  Int J Surg       Date:  2014-07-18       Impact factor: 6.071

4.  Botulinum toxin injection in epicardial fat pads can prevent recurrences of atrial fibrillation after cardiac surgery: results of a randomized pilot study.

Authors:  Evgeny Pokushalov; Boris Kozlov; Alexander Romanov; Artem Strelnikov; Sevda Bayramova; David Sergeevichev; Alexander Bogachev-Prokophiev; Sergey Zheleznev; Vladimir Shipulin; Nariman Salakhutdinov; Vladimir V Lomivorotov; Alexander Karaskov; Sunny S Po; Jonathan S Steinberg
Journal:  J Am Coll Cardiol       Date:  2014-08-12       Impact factor: 24.094

5.  Association between epicardial adipose tissue volumes on 3-dimensional reconstructed CT images and recurrence of atrial fibrillation after catheter ablation.

Authors:  Koichi Nagashima; Yasuo Okumura; Ichiro Watanabe; Toshiko Nakai; Kimie Ohkubo; Tatsuya Kofune; Masayoshi Kofune; Hiroaki Mano; Kazumasa Sonoda; Atsushi Hirayama
Journal:  Circ J       Date:  2011-08-26       Impact factor: 2.993

6.  Quantitative analysis of quantity and distribution of epicardial adipose tissue surrounding the left atrium in patients with atrial fibrillation and effect of recurrence after ablation.

Authors:  Hsuan-Ming Tsao; Wei-Chih Hu; Mei-Han Wu; Ching-Tai Tai; Yenn-Jiang Lin; Shih-Lin Chang; Li-Wei Lo; Yu-Feng Hu; Ta-Chuan Tuan; Tsu-Juey Wu; Ming-Huei Sheu; Cheng-Yen Chang; Shih-Ann Chen
Journal:  Am J Cardiol       Date:  2011-03-15       Impact factor: 2.778

7.  Epicardial adipose tissue-based defragmentation approach to persistent atrial fibrillation: its impact on complex fractionated electrograms and ablation outcome.

Authors:  Shiro Nakahara; Yuichi Hori; Sayuki Kobayashi; Yoshihiko Sakai; Isao Taguchi; Kan Takayanagi; Koichi Nagashima; Kazumasa Sonoda; Rikitake Kogawa; Naoko Sasaki; Ichiro Watanabe; Yasuo Okumura
Journal:  Heart Rhythm       Date:  2014-05-02       Impact factor: 6.343

8.  Eicosapentaenoic acid prevents atrial fibrillation associated with heart failure in a rabbit model.

Authors:  Kazuhisa Kitamura; Rei Shibata; Yukiomi Tsuji; Masayuki Shimano; Yasuya Inden; Toyoaki Murohara
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-02-18       Impact factor: 4.733

9.  Effect of intensive versus moderate lipid-lowering therapy on epicardial adipose tissue in hyperlipidemic post-menopausal women: a substudy of the BELLES trial (Beyond Endorsed Lipid Lowering with EBT Scanning).

Authors:  Nikolaos Alexopoulos; Bekir H Melek; Chesnal D Arepalli; Gregory-Randell Hartlage; Zhengjia Chen; Sungjin Kim; Arthur E Stillman; Paolo Raggi
Journal:  J Am Coll Cardiol       Date:  2013-03-14       Impact factor: 24.094

10.  Epicardial adipose tissue thickness and ablation outcome of atrial fibrillation.

Authors:  Tze-Fan Chao; Chung-Lieh Hung; Hsuan-Ming Tsao; Yenn-Jiang Lin; Chun-Ho Yun; Yau-Huei Lai; Shih-Lin Chang; Li-Wei Lo; Yu-Feng Hu; Ta-Chuan Tuan; Hung-Yu Chang; Jen-Yuan Kuo; Hung-I Yeh; Tsu-Juey Wu; Ming-Hsiung Hsieh; Wen-Chung Yu; Shih-Ann Chen
Journal:  PLoS One       Date:  2013-09-16       Impact factor: 3.240

View more
  16 in total

1.  Association between epicardial adipose tissue and recurrence of atrial fibrillation after ablation: a propensity score-matched analysis.

Authors:  Min Yang; Wenrui Bao; Zhihan Xu; Le Qin; Ning Zhang; Fuhua Yan; Wenjie Yang
Journal:  Int J Cardiovasc Imaging       Date:  2022-02-15       Impact factor: 2.357

2.  Epicardial adipose tissue affects the efficacy of left atrial posterior wall isolation for persistent atrial fibrillation.

Authors:  Yosuke Nakatani; Tamotsu Sakamoto; Yoshiaki Yamaguchi; Yasushi Tsujino; Koichiro Kinugawa
Journal:  J Arrhythm       Date:  2020-05-16

3.  European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on risk assessment in cardiac arrhythmias: use the right tool for the right outcome, in the right population.

Authors:  Jens Cosedis Nielsen; Yenn-Jiang Lin; Marcio Jansen de Oliveira Figueiredo; Alireza Sepehri Shamloo; Alberto Alfie; Serge Boveda; Nikolaos Dagres; Dario Di Toro; Lee L Eckhardt; Kenneth Ellenbogen; Carina Hardy; Takanori Ikeda; Aparna Jaswal; Elizabeth Kaufman; Andrew Krahn; Kengo Kusano; Valentina Kutyifa; Han S Lim; Gregory Y H Lip; Santiago Nava-Townsend; Hui-Nam Pak; Gerardo Rodríguez Diez; William Sauer; Anil Saxena; Jesper Hastrup Svendsen; Diego Vanegas; Marmar Vaseghi; Arthur Wilde; T Jared Bunch; Alfred E Buxton; Gonzalo Calvimontes; Tze-Fan Chao; Lars Eckardt; Heidi Estner; Anne M Gillis; Rodrigo Isa; Josef Kautzner; Philippe Maury; Joshua D Moss; Gi-Byung Nam; Brian Olshansky; Luis Fernando Pava Molano; Mauricio Pimentel; Mukund Prabhu; Wendy S Tzou; Philipp Sommer; Janice Swampillai; Alejandro Vidal; Thomas Deneke; Gerhard Hindricks; Christophe Leclercq
Journal:  Europace       Date:  2020-08-01       Impact factor: 5.214

4.  Disease-treatment interactions in the management of patients with obesity and diabetes who have atrial fibrillation: the potential mediating influence of epicardial adipose tissue.

Authors:  Milton Packer
Journal:  Cardiovasc Diabetol       Date:  2019-09-24       Impact factor: 9.951

Review 5.  Inflammation and Cardiovascular Diseases in the Elderly: The Role of Epicardial Adipose Tissue.

Authors:  Maddalena Conte; Laura Petraglia; Paolo Poggio; Vincenza Valerio; Serena Cabaro; Pasquale Campana; Giuseppe Comentale; Emilio Attena; Vincenzo Russo; Emanuele Pilato; Pietro Formisano; Dario Leosco; Valentina Parisi
Journal:  Front Med (Lausanne)       Date:  2022-02-15

6.  The importance of bipolar bidirectional radiofrequency in surgical AF ablation.

Authors:  Bart Maesen; Vanessa Weberndörfer; Elham Bidar; Dominik Linz
Journal:  Int J Cardiol Heart Vasc       Date:  2020-02-01

7.  Highlights from the International Journal of Cardiology Heart & Vasculature: Heart failure, atrial fibrillation, coronary artery disease and myocardial infarction.

Authors:  Dominik Linz; Enrico Ammirati; Gheorghe-Andrei Dan; Jordi Heijman; Dobromir Dobrev
Journal:  Int J Cardiol Heart Vasc       Date:  2019-11-20

8.  Inflammatory and lipid regulation by cholinergic activity in epicardial stromal cells from patients who underwent open-heart surgery.

Authors:  Marinela Couselo-Seijas; José N Lopez-Canoa; Ángel L Fernandez; Laila González-Melchor; Luisa M Seoane; Darío Duran-Muñoz; Adriana Rozados-Luis; José Ramón González-Juanatey; Moisés Rodríguez-Mañero; Sonia Eiras
Journal:  J Cell Mol Med       Date:  2020-08-07       Impact factor: 5.310

9.  Inflammation, atrial fibrillation, and the potential role for colchicine therapy.

Authors:  Bibin Varghese; David I Feldman; Christopher Chew; Eva Valilis; Roger S Blumenthal; Garima Sharma; Hugh Calkins
Journal:  Heart Rhythm O2       Date:  2021-04-02

Review 10.  21st Century Advances in Multimodality Imaging of Obesity for Care of the Cardiovascular Patient.

Authors:  Ian J Neeland; Takeshi Yokoo; Olof Dahlqvist Leinhard; Carl J Lavie
Journal:  JACC Cardiovasc Imaging       Date:  2020-04-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.